What if a single injection every few months could prevent heart attacks and strokes, challenging decades of daily pills and persistent risks? This bold vision drives Novartis, a pharmaceutical giant, as it stakes a $1.4 billion bet on Tourmaline Bio, a biotech firm with a promising drug candidate
In the ever-evolving landscape of the global pharmaceutical industry, strategic acquisitions often serve as a catalyst for monumental shifts in market dynamics, particularly in the United States, which stands as the largest pharmaceutical market worldwide. Imagine a mid-sized European company,
In 2025, the American health insurance landscape stands at a critical juncture, with an estimated 1.3 million individuals projected to lose coverage by 2026 due to sweeping legislative changes like the One Big Beautiful Bill Act, highlighting a growing crisis in healthcare access. This staggering
Setting the Stage for a Healthcare Cost Crisis In 2025, U.S. employers are staring down a daunting reality: health benefit costs per employee are projected to surge by an average of 6.5% in the coming year, marking the steepest increase in 15 years, and signaling a critical turning point for
Imagine a healthcare landscape where giants like UnitedHealth Group (UHG) and Walgreens are reshaping the very foundation of care delivery through billion-dollar mergers, setting a new standard for the industry. With UHG’s $3.3 billion acquisition of Amedisys and Sycamore Partners’ staggering $10 bi
In the realm of public health policy, few have navigated the complexities of Medicaid regulations as adeptly as Robert Gordon, former Michigan state health director. During his tenure, Gordon spearheaded the implementation of a controversial Medicaid work requirement, a policy he inherited under a
